Janssen has announced the findings of a new clinical trial demonstrating the benefits its drug Erleada can offer in the treatment of prostate cancer.

Data from the phase III SPARTAN clinical trial has demonstrated that treatment with Erleada, an investigational, next-generation androgen receptor inhibitor, can decrease the risk of metastasis or death by 72 percent in patients with non-metastatic castration-resistant prostate cancer.

“Janssen has announced new clinical trial data showing the effectiveness of Erleada in the treatment of prostate cancer.“

Median metastasis-free survival was also enhanced by more than two years among the patient group, who were selected based on rapid rises in their prostate-specific antigen status.

The results were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, and published in the New England Journal of Medicine. They represent the first clinical study findings to show that metastases can be delayed in this patient group.

Dr Peter Lebowitz, global therapeutic area head of oncology at Janssen Research and Development, said: "Janssen is committed to addressing unmet needs for treatment across all stages of disease progression with novel combinations and novel therapeutics."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.